Try our Advanced Search for more refined results

In re: Nexium Antitrust

  1. January 10, 2017

    1st Circ. Won't Rethink Nexium Pay-For-Delay Decision

    The First Circuit on Tuesday turned down bids by Nexium buyers for a rehearing of its November decision declining to revive a pay-for-delay class action against AstraZeneca and Ranbaxy over the heartburn medication.

  2. December 14, 2016

    Direct Buyers Push 1st Circ. To Rethink Nexium Suit

    The direct purchasers of heartburn medication Nexium have asked the First Circuit to reconsider its November dismissal of a class action alleging AstraZeneca PLC paid generics maker Ranbaxy Inc. to delay production of the drug's generic competitor, saying the decision ignores relevant precedents.

  3. November 21, 2016

    1st Circ. Won't Revive Nexium Pay-For-Delay Suit

    The First Circuit kept a 2014 jury verdict for AstraZeneca PLC and Ranbaxy Inc. intact, finding Monday that a class of direct and indirect buyers of heartburn medication Nexium who alleged antitrust violations had waived some arguments and were incorrect on others.

  4. October 05, 2016

    Buyers Ask 1st Circ. For Nexium Antitrust Case Redo

    Direct and indirect buyers of the heartburn medication Nexium asked a First Circuit panel for another shot at a pay-for-delay class action against AstraZeneca PLC and Ranbaxy Inc., arguing that the trial judge's erroneous summary judgment and evidentiary rulings tainted the verdict.

  5. May 19, 2016

    Nexium Pay-For-Delay Trial Needs Redo, Buyers Tell 1st Circ.

    Classes of direct buyers and end-payors of Nexium on Wednesday again pushed the First Circuit to grant a new trial after a district court rejected their claims that AstraZeneca's Hatch-Waxman Act settlement with Ranbaxy harmed competition, claiming the judge drew too-narrow conclusions and relied on misconceptions.

  6. April 18, 2016

    AstraZeneca, Ranbaxy Ask 1st Circ. To Affirm Nexium Win

    AstraZeneca PLC and Ranbaxy Inc. have told the First Circuit that it should affirm a Massachusetts federal court’s ruling that purchasers of AstraZeneca’s blockbuster heartburn drug Nexium couldn’t get a new trial after a jury sided with the drugmakers.

  7. February 16, 2016

    Nexium Ruling Could Hurt Antitrust Cases, FTC Tells 1st Circ.

    The Federal Trade Commission waded into the pay-for-delay case over AstraZeneca's blockbuster heartburn drug Nexium on Friday, telling the First Circuit that a trial court's "erroneous analysis" in the case threatens to impede enforcement of antitrust laws.

  8. February 08, 2016

    Nexium Buyers Push 1st Circ. For New Pay-For-Delay Trial

    Wholesalers, pharmacies and other Nexium buyers asked the First Circuit on Friday for another shot to prove their case that AstraZeneca and Ranbaxy inked an illegal pay-for-delay deal for the heartburn medication, arguing that "fundamental flaws" in the way the district court ran the class action mandated a new trial.